Novo Nordisk A/S

This study looks at the safety and effectiveness of Rybelsus, a pill for type 2 diabetes, in everyday medical practice in Korea. About 600 adults will take the medicine as their doctor prescribes, and researchers will track side effects and blood sugar control for 26 weeks. The g…

Researchers are testing how safely and comfortably people with type 2 diabetes can switch from semaglutide to CagriSema, a weekly injection that combines cagrilintide and semaglutide. About 210 adults who have taken a stable dose of branded semaglutide for at least three months w…

Researchers are studying zenagamtide, an experimental drug for overweight and obesity, to see how food and water affect the tablet version. Participants take zenagamtide as either a tablet or an injection, and the tablet group tries different meal timings and water amounts around…

This trial tests an experimental medicine called NNC0705-0002 in healthy adults. The drug aims to address conditions where inflammation may contribute to heart and metabolic problems. Researchers will give single and multiple oral doses to about 112 participants, some receiving a…

This Phase 3 trial will test whether a new drug called zenagamtide helps people with obesity lose more weight than the current treatment semaglutide. About 650 adults will receive weekly injections of either zenagamtide, semaglutide, or a placebo. The main goal is to see how much…

This phase 3 trial is testing whether an experimental once-daily oral drug called zenagamtide can safely help people with excess body weight lose weight. Around 950 adults aged 18 and older with overweight or obesity will be randomly assigned to receive either zenagamtide or a pl…

This Phase 3 study tests whether a weekly injection called zenagamtide helps Asian adults with overweight or obesity lose weight safely. About 400 participants will receive either the drug or a placebo for several weeks. The main goal is to see how much body weight changes, with …

This Phase 3 trial tests a new once-weekly injection, NNC0487-0111, against the approved drug semaglutide in 1000 adults with overweight or obesity and type 2 diabetes. Participants receive two weekly shots (active drug plus placebo) to see if the new drug is safe and leads to gr…

Researchers are studying how a single injection of the experimental medicine NNC0537-1482 moves through the body in people with different levels of kidney function. About 54 participants with normal, mildly, moderately, or severely reduced kidney function receive one dose under t…

This study looks at anonymized health records from about 100,000 people in a Turkish hospital network to see how common cardiometabolic conditions—like obesity, type 2 diabetes, heart disease, fatty liver, and kidney disease—are and how often they occur together. By tracking thes…

This study asks adults with haemophilia A in Germany to complete an online survey about their preferences for preventive treatments. Participants choose between hypothetical treatment options that vary in effectiveness, safety, and how they are given. The goal is to understand wh…

This early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…